Traded Nov 17, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Nov 7, 2025 · Filed Nov 8, 2025
The CFO of Lenz Therapeutics paid $454 out of pocket for Lenz Therapeutics shares. 1 other person at Lenz Therapeutics bought some too, in the same month.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$454
Shares × reported transaction price
<$25K
+0.6%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
2 days after results of Nov 5, 2025, 61 days before results of Jan 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded Nov 17, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Shawn Olsson (Chief Commercial Officer) sold ~$108K of Lenz Therapeutics
Scheduled in advanceShawn Olsson (Chief Commercial Officer) sold ~$153K of Lenz Therapeutics
Scheduled in advance